CMS enters agreement with Vertex, bluebird to improve access to gene therapies Dec 4 (Reuters) - The Centers for Medicare & Medicaid Services on Wednesday said it had entered into agreements with Vertex Pharmaceuticals VRTX.O and bluebird bio BLUE.O to help increase patient access to their gene therapies.
The so-called "outcomes-based agreements" will tie payments to whether the therapy improves health outcomes for patients who receive these drugs and are enrolled in government-backed Medicaid insurance plans.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments